The noradrenergic subtype of Parkinson disease: from animal models to clinical practice
| العنوان: | The noradrenergic subtype of Parkinson disease: from animal models to clinical practice |
|---|---|
| المؤلفون: | K. Ray Chaudhuri, Valentina Leta, Kirsty Bannister, David J. Brooks, Per Svenningsson |
| المصدر: | Ray Chaudhuri, K, Leta, V, Bannister, K, Brooks, D J & Svenningsson, P 2023, ' The noradrenergic subtype of Parkinson disease : from animal models to clinical practice ', Nature Reviews Neurology, vol. 19, no. 6, pp. 333-345 . https://doi.org/10.1038/s41582-023-00802-5Test |
| بيانات النشر: | Springer Science and Business Media LLC, 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Cellular and Molecular Neuroscience, Phenotype, Models, Animal, noradrenaline, Parkinson Disease/diagnosis, Animals, Primary Dysautonomias, Neurology (clinical), REM Sleep Behavior Disorder/diagnosis, PARKINSON DISEASE |
| الوصف: | Many advances in understanding the pathophysiology of Parkinson disease (PD) have been based on research addressing its motor symptoms and phenotypes. Various data-driven clinical phenotyping studies supported by neuropathological and in vivo neuroimaging data suggest the existence of distinct non-motor endophenotypes of PD even at diagnosis, a concept further strengthened by the predominantly non-motor spectrum of symptoms in prodromal PD. Preclinical and clinical studies support early dysfunction of noradrenergic transmission in both the CNS and peripheral nervous system circuits in patients with PD that results in a specific cluster of non-motor symptoms, including rapid eye movement sleep behaviour disorder, pain, anxiety and dysautonomia (particularly orthostatic hypotension and urinary dysfunction). Cluster analyses of large independent cohorts of patients with PD and phenotype-focused studies have confirmed the existence of a noradrenergic subtype of PD, which had been previously postulated but not fully characterized. This Review discusses the translational work that unravelled the clinical and neuropathological processes underpinning the noradrenergic PD subtype. Although some overlap with other PD subtypes is inevitable as the disease progresses, recognition of noradrenergic PD as a distinct early disease subtype represents an important advance towards the delivery of personalized medicine for patients with PD. |
| تدمد: | 1759-4766 1759-4758 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8171c7ec9faf988e9b2a17debe6c97a9Test https://doi.org/10.1038/s41582-023-00802-5Test |
| حقوق: | RESTRICTED |
| رقم الانضمام: | edsair.doi.dedup.....8171c7ec9faf988e9b2a17debe6c97a9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17594766 17594758 |
|---|